Zymeworks Inc

Zymeworks Inc. is a biopharmaceutical company. It engages in the discovery, development, and commercialization of multifunctional biotherapeutics, initially focused on the treatment of cancer. The company is headquartered in Middletown, DE.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zymeworks reports turnaround year with strong financials and R&D progress

Zymeworks delivered a strong financial performance in 2022, driven by revenue growth and cost management efforts.
The company faces challenges in managing increased expenses and addressing analyst inquiries on data disclosure and product development.
Despite challenges, Zymeworks remains well-positioned with ample cash resources and a robust R&D pipeline for future growth.
Opportunities lie in expanding partnerships, leveraging positive trial data, and showcasing innovation at upcoming industry events.

Zymeworks Inc reports revenue growth and strategic R&D advancements

Zymeworks Inc's Q1 2023 performance reflects positive financial trends and advancements in their R&D programs and partnerships.
While challenges exist with the Jazz agreement and future clinical trials, the company is strategically positioned for growth.
Opportunities in global collaborations, capital allocation, and innovative therapies position Zymeworks for future success and market expansion.

Zymeworks reports improved financials, advances global clinical expertise

Zymeworks Inc's Q2 2023 performance reflects a mixed financial picture with revenue growth but increased expenses, while maintaining a healthy cash position.
The company's strengths lie in advancing its product pipeline, leveraging partnerships for efficient development, and establishing global clinical expertise.
Challenges include timeline uncertainties, competitive landscape considerations, and operational complexities in clinical trial development.
Opportunities abound in therapeutic advancements, strategic partnerships, and long-term financial sustainability through disciplined management.

Zymeworks Inc reports improved financials and optimistic drug outlook

Zymeworks Inc's Q3 2023 performance reflects improved financials driven by revenue growth from collaborations, cost management strategies, and operational streamlining.
The company's strengths lie in new IND candidates, positive outlook on key drug opportunities, and confidence in study designs and treatment efficacy.
Challenges include managing expense trajectories, balancing cost structures, and optimizing cash resources for sustained operations and growth.
Opportunities abound in continued collaboration benefits, pipeline expansion in targeted cancer therapies, and advancements in preclinical assets for future clinical studies.

Zymeworks accelerates pipeline development with positive clinical results and partnerships

Zymeworks demonstrated positive performance in clinical trials and financial management in Q4 2023.
Strengths lie in pipeline progress, resource independence, and potential milestone payments.
Challenges include financial losses, competition, and the need for strategic partnerships.
Opportunities exist in partnerships, milestone payments, and upcoming data readouts for market impact.

Zymeworks Inc reports Q1 loss, focuses on T cell enhancement

Zymeworks Inc is strategically positioned to advance its clinical development programs and strengthen its presence in key locations for upcoming trials. The company is committed to executing its plan efficiently, focusing on enhancing T cell responses and exploring opportunities for sustainable growth.

Zymeworks reports Q2 losses, advances oncology pipeline with FDA clearances

Zymeworks' Q2 2024 performance reflects a mix of financial challenges and strategic advancements in drug development and regulatory milestones.
The company's strengths lie in its pipeline progress, strategic decision-making, and focus on growth through key appointments and partnerships.
While facing challenges in financial metrics and product timelines, Zymeworks has opportunities to leverage its resources for future growth and innovation.

Zymeworks reports revenue decline but showcases strength in innovation and financial strategy

Zymeworks reported a decline in revenue and a net loss for Q3 2024, reflecting ongoing financial challenges.
Despite this, the company showcased strengths in preclinical data, share repurchase program, and commitment to innovation.
Navigating market conditions and managing expenses will be crucial, but Zymeworks has opportunities in new therapeutic areas and strategic initiatives.
Investors should monitor the company's progress, especially with the upcoming R&D Day and potential advancements in its pipeline.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.

Zymeworks (ZYME) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zymeworks (ZYME) Upgraded to Buy: What Does It Mean for the Stock?

Ceragon Networks

Hims & Hers Health

Palantir Technologies

Block

Unisys

Zeta Global Holdings Corp

In the stock markets, fortunes rise and fall on the tide of hype and advancements, with the tech sector impacted the most. As the world is in the middle of a decade, the stage is set for the listed tech titans to emerge as veritable champions.

Next-Gen Winners: 7 Tech Stocks Set to Dominate the Decade

Zymeworks Inc. (NASDAQ:ZYME ) Q4 2023 Earnings Conference Call March 6, 2024 4:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Dr. Chris Astle - Senior Vice President and CFO Paul Moore - Chief Scientific Officer Ken Galbraith - Chair and CEO Conference Call Participants Stephen Willey - Stifel Ivy Wang - Jefferies Yigal Nochomovitz - Citigroup Brian Cheng - JPMorgan Jon Miller - Evercore ISI Operator Thank you for standing by. This is the conference operator.

Zymeworks Inc. (ZYME) Q4 2023 Earnings Call Transcript

Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to earnings of $4.65 per share a year ago.

Zymeworks Inc. (ZYME) Reports Q4 Loss, Misses Revenue Estimates

VANCOUVER, British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a summary of recent business highlights.

Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results

VANCOUVER, British Columbia, March 05, 2024 (GLOBE NEWSWIRE) --  Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced acceptance of five abstracts for poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place at the San Diego Convention Center in San Diego, CA from April 5-10, 2024.

Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting

Zymeworks' stock has increased by 67% since September, driven by developments in the antibody-drug conjugate sector. The company's lead asset, zanidatamab, is being developed for the treatment of first-line HER2-positive gastroesophageal adenocarcinoma. ZYME has a strong financial position, with a robust liquidity position and a cash runway that extends into 2027.

Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments

Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Zymeworks Inc. (ZYME) to Report a Decline in Earnings: What to Look Out for

RCM Technologies

Sun Country Airlines

Undervalued companies don't always have to be stocks with a significant decline in their share price. There is an abundance of solid companies that have experienced growth and share price appreciation.

3 Undervalued Small-Cap Stocks to Add to Your Must-Buy List

Global Ship Lease

Hudson Technologies

Nkarta, Inc.

SurgePays

Silvercorp Metals

The article lists seven small-cap stocks for those looking for opportunities that promise exponential return potential. From innovative biotech firms to edgy technology providers, small-cap stocks are making waves in various industries, offering the chance to capitalize on their leads.

Last Call! 7 Small-Cap Stocks Ready to Explode in Value

Arcos Dorados Hlds

BuildABear

Dorian LPG

Bank of N.T. Butterfield & Son

Ammo

Ring Energy

Investing in small-cap stocks offers multiple advantages for those looking to diversify their portfolios with potential high-growth opportunities efficiently. Small-cap stocks strike a unique balance between the relatively nascent microcap sphere and the more mature mid and large-cap segments.

7 Small-Cap Stocks With Significant Upside Potential in 2024

VANCOUVER, British Columbia, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its fourth quarter 2023 financial results after market close on March 6, 2024. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on March 6, 2024 at 4:30 pm Eastern Standard Time (EST).

Zymeworks To Host Fourth Quarter and Full Year 2023 Results Conference Call

VANCOUVER, British Columbia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Dr. Alessandra Cesano to its board of directors effective February 8, 2024.

Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors

Ardelyx

Natera

Biotechnology companies are within an ever-changing segment of the stock market. They are some of the most volatile stocks in the market, which may be why investors flock to or avoid these companies.

3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List

Zymeworks' share price is moving higher lately, led by an overall recovery of biotech stocks, and possibly by increased investor interest in the company's emerging antibody-drug conjugate platform. The topline results from the phase 3 trial of zanidatamab in patients with GEA are expected in late 2024, and are the most important event for the stock this year. Zanidatamab has the potential to become an important treatment option for GEA and patients, and potentially other HER2-positive cancers, and could generate significant royalties for Zymeworks if approved.

Zymeworks: Key Readout For Zanidatamab This Year And ADC Pipeline Expansion

Gigacloud Tech

The Bulls are back in charge on Wall Street. Major stock indices like the S&P 500 and Dow have powered to new highs recently, with the tech-heavy Nasdaq poised to follow.

3 Top Stocks to Buy This Winter for Sizzling Summer Gains

ZYME's partners, JAZZ and BGNE, are potentially within a year of approval and launch of zanidatamab, a bispecific anti-HER2 antibody. The approval and launch of zanidatamab in multiple markets could generate significant milestones and royalty streams for ZYME. ZYME projects that it has sufficient cash to last into H2 2027.

Zymeworks: Stock Emerges From Nearly 2 Years In The Doldrums, Thanks To An ADC Tailwind

Does Zymeworks Inc. (ZYME) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zymeworks Inc. (ZYME) Is Up 1.64% in One Week: What You Should Know

Unlocking the potential of small-cap stocks often reveals sky-bound potential. The three listed stocks in the article offer substantial growth opportunities.

$10K to $100K: Small-Cap Marvels With Massive Upside

VANCOUVER, British Columbia, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today provided an update on key strategic priorities for 2024 and 2025.

Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025

VANCOUVER, British Columbia, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced significant additions to its leadership team. These additions to the leadership team highlight Zymeworks' commitment to nurturing and advancing internal talent to key leadership roles while strengthening the capabilities and experience of the organization.

Zymeworks Announces Additional Leadership Appointments

VANCOUVER, British Columbia, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biopharmaceutical company developing novel, multifunctional biotherapeutics, today announced that it had entered into a securities purchase agreement with funds affiliated with EcoR1 Capital, LLC (“EcoR1 Capital”), for the sale of an aggregate of 5,086,521 pre-funded warrants to purchase 5,086,521 shares of common stock, $0.00001 par value per share, in a private placement. Each pre-funded warrant will be exercisable at an exercise price equal to $0.0001 per share, subject to adjustments as provided under the terms of the pre-funded warrant and will be exercisable at any time on or after the closing date, subject to a post-exercise beneficial ownership limitation of 19.99%.

Zymeworks Announces $50 Million Private Placement to EcoR1 Capital

D-MARKET Electronic Services

High Tide

As investors, small-cap stocks offer us the possibility of monumental returns. If you play your cards right, small-caps can deliver gains most blue chips could never match.

Small-Cap Sensations: 3 Stocks Predicted for Massive Growth in 2024

Bitfarms Ltd

Spok Holdings

In the pulsating realm of small-cap stocks, a select few emerge as trailblazers, poised to revolutionize industries and redefine investment landscapes. Enter the triumphant trio of three under-the-radar companies orchestrating remarkable healthcare, biotechnology and cryptocurrency mining feats.

From $10k to $100k in 5 years: 3 Small-Cap Stocks to Make a Fortune

Recursion Pharmaceuticals

Vertex Pharmaceuticals

On the heels of the devastating COVID-19 pandemic, investor enthusiasm for biotech stocks waned as the Federal Reserve embarked on its aggressive rate-hiking campaign to bring down the red-hot inflation that ensued.

News for Zymeworks Inc Stock (ZYME)